To confirm the risk of chest wall tract metastases following chest wall intervention for malignant pleural mesothelioma (MPM), we reviewed our institutional experience. Between 2006 and 2010, 14 patients with MPM underwent chest wall intervention for diagnosis in Kyoto University Hospital. Seven of them underwent extrapleural pneumonectomy (EPP) after the diagnosis, while seven did not undergo EPP. All patients did not show any macroscopic abnormalities around the biopsy sites suggesting chest wall tract metastases. In the seven EPP patients, tissues including the chest wall tract, which were removed were investigated pathologically for possible metastases. In two of these seven patients, diffuse extension of MPM along the chest wall tract was pathologically confirmed. In these two patients, the period between pleural biopsy and EPP was relatively short in comparison with that in the other five patients. Despite the small number of cases, the importance of resection of the chest wall tract for the diagnostic intervention might be implied at EPP.
Introduction
Malignant pleural mesothelioma (MPM) is an aggressive and universally fatal tumor. It has been stated that patients with MPM, who undergo chest instrumentation, might develop seeding at the site of the intervention, leading to a subcutaneous tumor. Prophylactic radiotherapy to sites of pleural intervention has been advocated in many guidelines to prevent tract metastases w1-3x. However, after several recent randomized control trials w4-6x, no consensus has been reached to support the use of prophylactic radiotherapy. To confirm the risk of chest wall tract metastases following chest wall intervention for such tumors, we reviewed our institutional experience.
Patients and methods
Between 2006 and 2010, 14 patients with MPM underwent chest wall intervention for diagnosis in our institution. After the diagnosis of MPM, seven patients who were considered tolerable with trimodality therapy underwent extrapleural pneumonectomy (EPP), followed by chemotherapy and radiotherapy. The details of the trimodality therapy were described elsewhere w7x. In these patients, tissues including the chest wall tract, which were removed at EPP, were investigated pathologically for possible metastases. The other seven patients did not undergo EPP after the confirmation of pathological diagnosis. Various variables including patients' age and gender, diagnostic procedures, interval between biopsy and surgery, histology, treatment, and survival after the confirmation of diagnosis by biopsy were investigated retrospectively.
Results
All the data were summarized in Table 1 . Video-assisted thoracoscopic pleural biopsy was performed through one port in 13 patients. In all patients, there were no macroscopic abnormalities around the biopsy sites suggesting chest wall tract metastases. There were seven patients who were planned to undergo EPP followed by chemotherapy and radiation therapy. However, only five of the seven patients completed the planned treatment. The other two patients (patients 1 and 3) unfortunately could not proceed with the next mode of therapy. Patient 1 died from MPM recurrence in the pericardial sac three months after surgery. Patient 3 died from a sudden bleeding one week after surgery. In two of seven patients with EPP (patients 1 and 4), an extension of mesothelioma along the chest wall tract was pathologically confirmed. In patient 1, the tumor extended diffusely along the intervention tract up to the intercostal muscle, while, in patient 4, the tumor extended diffusely along the intervention tract just beneath the derma (Fig. 1) . The median period between pleural biopsy and EPP was 31 days, but the period between pleural biopsy and EPP was 14 and 19 days in these two patients. In patient 1, EPP was performed two weeks after videoassisted thoracoscopic pleural biopsy. The patient was com- plicated with suspicious empyema one month after surgery, requiring prolonged admission. Two months after surgery, he presented with recurrent MPM in the pericardium and died soon after recurrence. In patient 4, EPP was performed almost three weeks after video-assisted thoracoscopic pleural biopsy. Aortic dissection was accidentally found and chemotherapy was postponed for three months. He was then treated with chemotherapy and intensity modulated radiation therapy, but recurrent MPM was found in the peritoneum 10 months after surgery. He died one year after the diagnosis.
In one patient (patient 9), surgical resection had been initially considered after chemotherapy, but it was declined since disseminated lesions in the pericardiac sac were identified at surgical extirpation. The other six patients were initially considered unfit for surgery with multimodality treatment on the confirmation of pathological diagnosis. Four of six patients underwent chemotherapy, but one died five months after the diagnosis, another chose best supportive care (BSC) four months after the diagnosis, and the other two were still receiving chemotherapy 11 and 64 months after the diagnosis. However, the other two patients chose BSC and died three and 13 months after the diagnosis, respectively. Thus, seven patients who did not receive EPP did not show any signs or symptoms related to chest wall tract metastases, although no pathological samples were obtained.
Discussion
Patients with MPM usually require pleural aspiration, pleural biopsy or thoracoscopy during diagnosis. Following these procedures there is a recognized risk of malignant seeding along the track of the needle or trocar, causing subcutaneous nodule formation. The standard of care has been to offer prophylactic irradiation following these procedures w4, 8x; however, the evidence that this reduces nodule formation or improves quality of life is questionable w5, 6x.
In our study, despite the small number of cases, there were no patients with problems related to chest wall tract metastases after the diagnostic intervention. Since no patients received prophylactic chest wall irradiation in our series, no significant suggestions about the preventive chest wall radiation were drawn from our institutional experience. All the aforementioned studies used tract metastases as their endpoint, whether they were symptomatic or not. In the trials as well as in clinical practice, needle track metastases were diagnosed clinically and rarely sampled for histological confirmation. In our study, two patients presented with diffuse tumor extension along the chest wall tract. Interestingly enough, in both patients, EPP was performed relatively early after the pleural biopsy in comparison with the other five cases. Both patients also died within one year after EPP with tumor recurrence in the pericardium and peritoneum. This clinical course and pathological findings strongly suggested the tumor developed aggressively to the adjacent spaces as well as the chest wall tract. The relationship between the tumor extension along the chest wall tract and the degree of tumor malignancy could not be solved because of this small number of cases, but this might be investigated in large-scale randomized multi-center clinical trials. Furthermore, in MPM treatment, surgical therapy has been recently questioned in terms of absolute benefit on survival, thus not only chest wall tract resection results but EPP results should be interpreted with caution.
In conclusion, diffuse tumor extension along chest wall tract was confirmed in two of seven patients with EPP. Despite the small number of cases, the importance of resection of the chest wall tract for the diagnostic intervention might be implied at EPP.
